国家癌症中心

Tumour infiltrating lymphocytes (TILs) are a key component of the tumour microenvironment. To establish a clinically relevant TILs cut-off for patients with oesophago-gastric (OG) cancer, it is essential to know whether TILs density varies by patient and/or disease characteristics. TILs were quantified as TILs/mm2 (TILs density) by a deep-learning algorithm applied to digitised Haematoxylin/Eosin (H E)-stained biopsies and resection specimens from 4628 patients from nine phase III trials. 4533 patients with TILs density and matched clinicopathological data were included in the final analyses. Associations between TILs density, disease stage, geographical region (UK versus Asia), sex, age, and treatment were analysed. Median TILs density was higher in pre-treatment biopsies from patients with early-stage versus late-stage disease (962 vs 479 TILs/mm2, p < 0.001). Within the same geographical region and disease stage, TILs density was similar across different chemotherapy regimens. In UK-led trials of early-stage disease, post-chemotherapy resections showed higher TILs density than chemotherapy-naïve resections (618 vs 571 TILs/mm2, p = 0.003). TILs density was higher in Asian tumours compared to UK tumours (1419 vs 571 TILs/mm2, p < 0.001). No significant associations were observed with age or sex. This is the largest study to date evaluating TILs density in OG cancer. TILs density varied with stage and geographical region but not by age or sex. These findings may explain enhanced response to immunotherapy observed in published studies of patients with early-stage disease and highlight the need to account for baseline TILs heterogeneity when interpreting TILs as a possible biomarker in future studies.

Argon plasma coagulation (APC) has been proposed for the treatment of gastric low-grade dysplasia (LGD), but comparative data with endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are insufficient. We investigated the clinical outcomes of APC, EMR, and ESD for small gastric LGD. We retrospectively included 2128 patients treated with APC (n = 799), EMR (n = 404), or ESD (n = 925) for gastric LGD ≤ 20 mm at 12 tertiary centers in Korea between 2017 and 2021. Local recurrence and adverse events (AEs) were evaluated. To minimize selection bias, inverse probability of treatment weighting (IPTW) was applied. The overall incidence of AEs was significantly lower in the APC group (0.8

Importance:The unexplored quality of evidence supporting online video claims by medical professionals creates a credibility-evidence gap that threatens the principles of evidence-based medicine. Objective:To systematically evaluate the evidence hierarchy supporting medical claims in health care professional-created online videos using a novel evidence classification framework. Design, Setting, and Participants:In this quality improvement study using a cross-sectional analysis, YouTube was searched using cancer- and diabetes-related terms. A total of 309 videos met the inclusion criteria. The video search, data extraction, and archiving were conducted between June 20 and 21, 2025, to create a static dataset. Videos were assessed using the newly developed Evidence-GRADE (E-GRADE [Grading of Recommendations Assessment, Development and Evaluation]) framework, categorizing evidence into 4 levels: grade A (high certainty from systematic reviews and/or guidelines), grade B (moderate certainty from randomized clinical trials, cohort studies, and high-quality observational studies with clear citations), grade C (low certainty from limited observational studies, physiological mechanisms, or case series without critical appraisal), and grade D (very low or no certainty from anecdotal evidence). Exposure:Videos that had a minimum of 10 000 views, were created by health care professionals, had a minimum duration of 1 minute, and contained specific health claims. Main Outcomes and Measures:Primary outcomes included the distribution of evidence grades (A-D) supporting medical claims. Secondary outcomes included correlations between evidence quality and engagement metrics (views and likes) and traditional quality scores (DISCERN, JAMA benchmark criteria, and Global Quality Scale). Results:Among the 309 videos included, which had a median of 164 454 (IQR, 58 909-477 075) views, most medical claims (193 [62.5%]) were supported by very low or no evidence (grade D), while only 61 claims (19.7%) were supported by high-quality evidence (grade A). Moderate (grade B) and low (grade C) evidence levels were found in 45 (14.6%) and 10 (3.2%) videos, respectively. The correlation with view counts was statistically significant for grade D videos, which were associated with a 34.6% higher view count (incidence rate ratio, 1.35; 95% CI, 1.00-1.81; P = .047) than grade A videos. Traditional quality tools showed only weak correlations (range of coefficients, 0.11-0.23) with evidence levels, thus failing to detect important qualitative differences. Conclusions and Relevance:In this quality improvement study, a substantial credibility-evidence gap was found in physician-generated video-sharing content, where medical authorities often legitimized claims lacking robust empirical support. These findings emphasize the need for evidence-based content guidelines and enhanced science communication training for health care professionals to maintain scientific integrity in digital health information.

BACKGROUND:Tegoprazan, a potassium-competitive acid blocker, offers potent and sustained acid inhibition and potentially improves eradication efficacy. AIM:This study aimed to evaluate the efficacy and safety of tegoprazan-based triple therapy with two dosing regimens compared with that of lansoprazole-based therapy for first-line Helicobacter pylori eradication. METHODS:This randomized, double-blind, active-controlled, multicenter trial was conducted at 19 referral hospitals in South Korea (February 2023-April 2024). Treatment-naïve adults with H. pylori infection were randomized 1:1:1 to receive 14-day triple therapy with tegoprazan, 50 mg (TAC1), tegoprazan, 100 mg (TAC2), or lansoprazole, 30 mg (LAC), each combined with amoxicillin 1000 mg and clarithromycin 500 mg, administered twice daily. The primary endpoint was H. pylori eradication rate in the modified intention-to-treat (mITT) population, with a non-inferiority margin of -10%. Secondary endpoints included subgroup analyses based on clarithromycin resistance and safety assessments. RESULTS:Of the 564 screened patients, 382 were randomized. In the mITT analysis (mean age, 54.9 years; 54.3% male), eradication rates were 86.0%, 85.5%, and 78.7% for TAC1, TAC2, and LAC, respectively. Both tegoprazan-based regimens met the non-inferiority criteria. Among clarithromycin-resistant infections, the eradication rates were higher for TAC1 (47.8%) and TAC2 (50.0%) than for LAC (35.5%), although the difference was not statistically significant. Safety profiles were comparable across the groups, with no serious drug-related adverse events. CONCLUSION:Tegoprazan-based triple therapies, at 50- and 100-mg doses, were non-inferior to lansoprazole-based therapy and were well tolerated. Our findings indicated that tegoprazan-based triple therapy is a viable first-line option for H. pylori eradication. TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT05933031.